Core Viewpoint - UBI has reduced its stake in Shenglian Bio (600201) by 12,319,240 shares, representing 3% of the total share capital, decreasing its ownership from 10.52% to 7.52% [1] Group 1: Shareholding Changes - UBI's share reduction was executed at a price range of 8.80-9.89 CNY per share, totaling approximately 111 million CNY [1] - The reduction plan commenced on November 13, 2025, and was completed on February 9, 2026, without changing the controlling shareholder or actual controller of the company [1] Group 2: Financial Performance - Shenglian Bio anticipates a net loss of approximately 20 million CNY for 2025, which is a 55% improvement compared to the 2024 loss [1] - The adjusted net loss is expected to be around 23.5 million CNY, reflecting a 51% reduction [1] - The improvement in losses is attributed to cost reduction and efficiency enhancement, despite increased competition in the animal health industry leading to lower product prices and higher accounts receivable impairment losses [1][3] Group 3: Stock Performance - Over the past week (February 5 to 11, 2026), Shenglian Bio's stock price fluctuated by 3.63%, with a high of 9.87 CNY on February 10 and a low of 9.24 CNY on February 6 [2] - Following the completion of the share reduction announcement on February 9, the stock price rose by 3.32% with a trading volume increase (turnover rate of 1.06%) [2] - On February 11, the closing price was 9.71 CNY, reflecting a single-day increase of 1.04% [2]

Core Viewpoint - The National Medical Products Administration (NMPA) has released the "Technical Guidelines for Clinical Trials of Multivalent Vaccines" to support the high-quality development of the vaccine industry and accelerate the research and market launch of domestic multivalent vaccines [1] Group 1: Guidelines Overview - The guidelines include considerations for topic selection, clinical trial design, and post-marketing changes, specifically applicable to the clinical development of multivalent vaccines [1] Group 2: Importance of Multivalent Vaccines - Multivalent vaccines contain antigens related to different pathogens and are defined based on biological taxonomy by "species" [1] - These vaccines simplify immunization schedules, reduce the number of vaccinations required, and enhance the convenience and compliance of vaccination, which is crucial for increasing vaccination rates and alleviating public health burdens [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [5][10]. Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, with operating income reaching 1.708 billion yuan, a year-on-year growth of 20.53%, and a net profit attributable to shareholders of 257 million yuan, up 57.59% [3][4]. - The economic animal health segment is performing steadily, while the pet health segment is emerging as a new strategic direction, contributing to long-term growth [5][4]. - The company is focusing on large customer strategies and has established strategic partnerships with leading breeding groups, enhancing its market share through brand strength and product quality [4]. Financial Summary - The company expects its earnings per share (EPS) to be 0.99 yuan, 1.27 yuan, and 1.40 yuan for the years 2025, 2026, and 2027 respectively [5][6]. - Projected operating revenues for 2024 to 2027 are 3.070 billion yuan, 3.650 billion yuan, 4.221 billion yuan, and 4.692 billion yuan, with growth rates of 13.32%, 18.90%, 15.64%, and 11.14% respectively [6][9]. - The company's net profit attributable to shareholders is forecasted to be 300.72 million yuan in 2024, increasing to 650.39 million yuan by 2027, reflecting a growth rate of -33.70% in 2024 followed by positive growth in subsequent years [6][9].